Pfizer Inc. [NYSE: PFE] has declared the acquisition of Amplyx Pharmaceuticals on Wednesday. Amplyx has gained recognition as a private firm that has pledged to the advancement of therapies for critical illnesses that afflict people with imperiled immune systems.
Presently, the top candidate of the firm is Fosmanogepix (APX001). It is a novel examination asset under progress for the therapy of invasive fungal infections. Each year the world has reported more than 1.5 million cases of invasive fungal infection.
Furthermore, the world has experienced a mortality rate as high as 30-80% across infection types. Fosmanogepix has the ability to target fungal strains repellent to the standard of care therapy. Presently, there are only three classes of antifungal remedies.
The new cure of Amplyx is a ray of hope for both physicians and sufferers. US FDA has not provided any authorization to any novel therapeutic class of antifungal therapies in nearly two decades.
Fosmanogepix Phase II Clinical Trials
Fosmanogepix is presently in Phase II clinical study. The purpose of the study is to assess the safety and potency of both intravenous (IV) and oral formulations for the cure of sufferers with critical invasive fungal infections caused by molds, yeasts, and rare molds.
Furthermore, with this buying of Ampylyx PFE not only acquire Fosmanogepix but also got the ownership of Amplyx’s early-stage pipeline that involves potential antiviral (MAU868) and antifungal (APX2039) cures. The firm has not yet disclosed the terms of the agreement.